Biological performance of a polycaprolactone-based scaffold used as fusion cage device in a large animal model of spinal reconstructive surgery

A bioactive and bioresorbable scaffold fabricated from medical grade poly (epsilon-caprolactone) and\ud incorporating 20% beta-tricalcium phosphate (mPCL–TCP) was recently developed for bone regeneration\ud at load bearing sites. In the present study, we aimed to evaluate bone ingrowth into mPCL–TCP in a large\ud animal model of lumbar interbody fusion. Six pigs underwent a 2-level (L3/4; L5/6) anterior lumbar\ud interbody fusion (ALIF) implanted with mPCL–TCP þ 0.6 mg rhBMP-2 as treatment group while four\ud other pigs implanted with autogenous bone graft served as control. Computed tomographic scanning and\ud histology revealed complete defect bridging in all (100%) specimen from the treatment group as early as\ud 3 months. Histological evidence of continuing bone remodeling and maturation was observed at 6\ud months. In the control group, only partial bridging was observed at 3 months and only 50% of segments\ud in this group showed complete defect bridging at 6 months. Furthermore, 25% of segments in the control\ud group showed evidence of graft fracture, resorption and pseudoarthrosis. In contrast, no evidence of graft\ud fractures, pseudoarthrosis or foreign body reaction was observed in the treatment group. These results\ud reveal that mPCL–TCP scaffolds could act as bone graft substitutes by providing a suitable environment\ud for bone regeneration in a dynamic load bearing setting such as in a porcine model of interbody spine\ud fusion